Erdafitinib - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for erdafitinib and what is the scope of freedom to operate?
Erdafitinib
is the generic ingredient in one branded drug marketed by Janssen Biotech and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.Erdafitinib has one hundred and eighty-one patent family members in forty-two countries.
One supplier is listed for this compound.
Summary for erdafitinib
International Patents: | 181 |
US Patents: | 6 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 50 |
Clinical Trials: | 27 |
Patent Applications: | 672 |
What excipients (inactive ingredients) are in erdafitinib? | erdafitinib excipients list |
DailyMed Link: | erdafitinib at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for erdafitinib
Generic Entry Date for erdafitinib*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for erdafitinib
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Memorial Sloan Kettering Cancer Center | Phase 2 |
M.D. Anderson Cancer Center | Phase 2 |
University of Washington | Phase 2 |
Pharmacology for erdafitinib
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Poland | 3122742 | ⤷ Try a Trial | |
Singapore | 10202105110V | CANCER TREATMENT | ⤷ Try a Trial |
Slovenia | 2563775 | ⤷ Try a Trial | |
Poland | 2563775 | ⤷ Try a Trial | |
Mexico | 2017010287 | COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN N-(3,5-DIMETOXIFENIL)-N '-(1-METILETIL)-N-[3-(1-METIL-1H-PIRAZOL-4-IL)QUINOXALIN-6-IL]ETA NO-1,2-DIAMINA. (PHARMACEUTICAL COMPOSITIONS COMPRISING N-(3,5-DIMETHOXYPHENYL)-N' -(1-METHYLETHYL)-N-[3-(1-METHYL-1H-PYRAZOL-4-YL)QUINOXALIN-6-YL] ETHANE-1,2-DIAMINE.) | ⤷ Try a Trial |
Eurasian Patent Organization | 201500278 | ПИРАЗОЛИЛХИНАЗОЛИНОВЫЕ ИНГИБИТОРЫ КИНАЗЫ | ⤷ Try a Trial |
Portugal | 2563775 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:






Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.